Document:

Warrant to Purchase Common Stock

 Exhibit 4.10 
 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN
EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE
STATE SECURITIES LAWS. 
 WARRANT AGREEMENT 
 To Purchase Shares of the Common Stock of 
 Coronado Biosciences, Inc.

 Dated as of August 28, 2012 (the “Effective Date”) 

WHEREAS, Coronado Biosciences, Inc., a Delaware corporation (the “Company”), has entered into a Loan and Security
Agreement of even date herewith (as amended and in effect from time to time, the “Loan Agreement”) with Hercules Technology Growth Capital, Inc., a Maryland corporation (the “Warrantholder”); 

WHEREAS, the Company desires to grant to Warrantholder, in consideration for, among other things, the financial accommodations provided
for in the Loan Agreement, the right to purchase shares of its Common Stock pursuant to this Warrant Agreement (this “Warrant” or this “Agreement”); 

NOW, THEREFORE, in consideration of the Warrantholder executing and delivering the Loan Agreement and providing the financial
accommodations contemplated therein, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows: 
 SECTION 1. GRANT OF THE RIGHT TO PURCHASE COMMON STOCK. 
 (a) For value
received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to the conditions hereinafter set forth, to subscribe for and purchase, from the Company, up to 73,009 shares of Common Stock (as
defined below), at a purchase per share of $5.65 (the “Exercise Price”). The number and Exercise Price of such shares are subject to adjustment as provided in Section 8. As used herein, the following terms shall have the
following meanings: 
 “Act” means the Securities Act of 1933, as amended. 

“Charter” means the Company’s Certificate of Incorporation or other constitutional document, as may
be amended and in effect from time to time. 
 “Common Stock” means the Company’s common
stock, $0.001 par value per share, as presently constituted under the Charter, and any class and/or series of Company capital stock for or into which such common stock may be converted or exchanged in a reorganization, recapitalization or similar
transaction; 

 “Merger Event” means a merger or consolidation of the
Company into or with another entity, in which the shareholders of the Company as of immediately prior to the closing of the transaction own securities representing less than a majority of the total outstanding combined voting equity of the successor
or surviving entity as of immediately after the closing of the transaction. 
 “Purchase Price” means, with
respect to any exercise of this Warrant, an amount equal to the then-effective Exercise Price multiplied by the number of shares of Common Stock as to which this Warrant is then exercised. 

SECTION 2. TERM OF THE AGREEMENT. 
 Except as otherwise provided for herein, the term of this Agreement and the right to purchase Common Stock as granted herein shall commence on the Effective Date and shall be exercisable for a period
ending upon the seventh (7th) anniversary of the
Effective Date. 
 SECTION 3. EXERCISE OF THE PURCHASE RIGHTS. 

(a) Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any
time, or from time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I (the “Notice of
Exercise”), duly completed and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below, and in no event later than three (3) days thereafter, the
Company shall issue to the Warrantholder a certificate for the number of shares of Common Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto as Exhibit II (the “Acknowledgment of
Exercise”) indicating the number of shares which remain subject to future purchases, if any. 
 The Purchase Price may
be paid at the Warrantholder’s election either (i) by cash or check, or (ii) by surrender of all or a portion of the Warrant for shares of Common Stock to be exercised under this Agreement and, if applicable, an amended Agreement
representing the remaining number of shares purchasable hereunder, as determined below (“Net Issuance”). If the Warrantholder elects the Net Issuance method, the Company will issue shares of Common Stock in accordance with the
following formula: 
  

					
		 	X = Y(A-B)	  	
		 	           A	  	

  

			
	Where:	 	X = the number of shares of Common Stock to be issued to the Warrantholder.
		
		 	Y = the number of shares of Common Stock requested to be exercised under this Agreement.
		
		 	A = the then-current fair market value of one (1) share of Common Stock at the time of exercise.
		
		 	B = the Exercise Price.

 For purposes of the above calculation, current fair market value of shares of Common Stock shall mean
with respect to each share of Common Stock: 
 (i) at all times when the Common Stock shall be listed or quoted for trading on a
national securities exchange or inter-dealer quotation system, the average of the closing prices of a share of Common Stock for the ten (10) trading days immediately preceding the date of determination; 

  
 2 

 (ii) if the exercise is in connection with a Merger Event, the fair market value of a share
of Common Stock shall be deemed to be the per share value received by the holders of the outstanding shares of Common Stock pursuant to such Merger Event as determined in accordance with the definitive transaction documents executed among the
parties in connection therewith; or 
 (iii) in cases other than as described in the foregoing clauses (i) and (ii), the
current fair market value of a share of Common Stock shall be determined in good faith by the Company’s Board of Directors. 
 Upon partial exercise by either cash or Net Issuance, prior to the expiration or earlier termination hereof, the Company shall promptly issue an amended Agreement representing the remaining number of
shares purchasable hereunder. All other terms and conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to the Effective Date hereof. 

(b) Exercise Prior to Expiration. To the extent this Warrant is not previously exercised as to all shares subject hereto, and if
the fair market value of one share of Common Stock is greater than the Exercise Price then in effect, this Agreement shall be deemed automatically exercised on a Net Issuance basis pursuant to Section 3(a) (even if not surrendered) as of
immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share of Common Stock upon such expiration shall be determined pursuant to Section 3(a). To the extent this Warrant or any portion hereof
is deemed automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Common Stock if any, the Warrantholder is to receive by reason of such automatic exercise, and
to issue a certificate to Warrantholder evidencing such shares. 
 SECTION 4. RESERVATION OF SHARES. 

During the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of its Common
Stock to provide for the exercise of the rights to purchase Common Stock as provided for herein. 
 SECTION 5. NO
FRACTIONAL SHARES OR SCRIP. 
 No fractional shares or scrip representing fractional shares shall be issued upon the exercise of
this Agreement, but in lieu of such fractional shares the Company shall make a cash payment therefor upon the basis of the Exercise Price then in effect. 
 SECTION 6. NO RIGHTS AS SHAREHOLDER/STOCKHOLDER. 
 Without limitation of
any provision hereof, Warrantholder agrees that this Agreement does not entitle the Warrantholder to any voting rights or other rights as a shareholder/stockholder of the Company prior to the exercise of any of the purchase rights set forth in this
Agreement. 

  
 3 

 SECTION 7. WARRANTHOLDER REGISTRY. 

The Company shall maintain a registry showing the name and address of the registered holder of this Agreement. Warrantholder’s
initial address, for purposes of such registry, is set forth in Section 12(g) below. Warrantholder may change such address by giving written notice of such changed address to the Company. 

SECTION 8. ADJUSTMENT RIGHTS. 
 The Exercise Price and the number of shares of Common Stock purchasable hereunder are subject to adjustment, as follows: 
 (a) Merger Event. If at any time there shall be Merger Event, then, as a part of such Merger Event, lawful provision shall be made so that the Warrantholder shall thereafter be entitled to receive,
upon exercise of this Agreement, the number of shares of preferred stock or other securities, cash or other property of the successor corporation resulting from such Merger Event that would have been issuable if Warrantholder had exercised this
Agreement immediately prior to the Merger Event. Following any Merger Event, the term Initial Shares and Additional Shares, if any, shall be deemed to refer to the shares for which this Agreement is thereafter exercisable in accordance with the
provisions hereof. 
 (b) Reclassification of Shares. Except as set forth in Section 8(a), if the Company at any
time shall, by combination, reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Agreement exist into the same or a different number of securities of any other
class or classes, this Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights
under this Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change. 
 (c)
Subdivision or Combination of Shares. If the Company at any time shall combine or subdivide its Common Stock, (i) in the case of a subdivision, the Exercise Price shall be proportionately decreased, and the number of shares of Common
Stock issuable upon exercise of this Agreement shall be proportionately increased, or (ii) in the case of a combination, the Exercise Price shall be proportionately increased, and the number of shares of Common Stock issuable upon the exercise
of this Agreement shall be proportionately decreased. 
 (d) Stock Dividends. If the Company at any time while this
Agreement is outstanding and unexpired shall: 
 (i) pay a dividend with respect to the Common Stock payable in
Common Stock, then the Exercise Price shall be adjusted, from and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately
prior to such date of determination by a fraction (A) the numerator of which shall be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the
total number of shares of Common Stock outstanding immediately after such dividend or distribution; or 
 (ii)
make any other distribution with respect to Common Stock (other than a regular cash dividend out of undistributed net income) except any distribution specifically provided for in any other clause of this Section 8, then, in each such case,
provision shall be made by the Company such that the Warrantholder shall receive upon exercise of this Warrant a proportionate share of any such distribution as though it were the holder of the Common Stock as of the record date fixed for the
determination of the stockholders of the Company entitled to receive such distribution. 

  
 4 

 (e) Notice of Adjustments. If: (i) the Company shall declare any dividend or
distribution upon its outstanding Common Stock, payable in stock, cash, property or other securities (assuming Warrantholder in its capacity as lender under the Loan Agreement consents to such dividend); (ii) the Company shall offer for
subscription pro rata to the holders of its Common Stock any additional shares of stock of any class or other rights; (iii) there shall be any Merger Event; (iv) the Company shall sell, lease, license or otherwise transfer all or
substantially all of its assets; or (v) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event, the Company shall give the Warrantholder notice thereof at the same time and
in the same manner as it gives notice thereof to the holders of Common Stock. 
 SECTION 9. REPRESENTATIONS, WARRANTIES
AND COVENANTS OF THE COMPANY. 
 (a) Reservation of Common Stock. The Company covenants and agrees that all Initial
Shares and Additional Shares, if any, that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable. The Company further covenants and agrees that
the Company will, at all times during the term hereof, have authorized and reserved, free from preemptive rights, a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by this Warrant. If at any time
during the term hereof the number of authorized but unissued shares of Common Stock shall not be sufficient to permit exercise of this Warrant in full, the Company will take such corporate action as may, in the opinion of its counsel, be necessary
to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes. 
 (b) Due Authority. The execution and delivery by the Company of this Agreement and the performance of all obligations of the Company hereunder, including the issuance to Warrantholder of the right
to acquire the shares of Common Stock, have been duly authorized by all necessary corporate action on the part of the Company. This Agreement: (1) does not violate the Company’s Charter or current bylaws; (2) does not contravene any
law or governmental rule, regulation or order applicable to it; and (3) does not and will not contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument to which it is a party or by which
it is bound. This Agreement constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with its terms. 
 (c) Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, federal or other governmental authority or
agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Agreement, except for the filing of notices pursuant to Regulation D under the Act and any filing required by applicable state
securities law, which filings will be effective by the time required thereby. 
 (d) Issued Securities. All issued and
outstanding shares of Common Stock and other securities of the Company have been duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common Stock and other securities were issued in full compliance with
all federal and state securities laws. 
 (e) Insurance. The Company has in full force and effect insurance policies,
with extended coverage, insuring the Company and its property and business against such losses and risks, and in such amounts, as are customary for corporations engaged in a similar business and similarly situated and as otherwise may be required
pursuant to the terms of any other contract or agreement. 

  
 5 

 (f) Exempt Transaction. Subject to the accuracy of the Warrantholder’s
representations in Section 10, the issuance of the Common Stock upon exercise of this Agreement will constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act, in reliance upon Section 4(2)
thereof, and (ii) the qualification requirements of the applicable state securities laws. 
 (g) Registration
Rights. The Company covenants and agrees with Warrantholder that if the Company, at any time and from time to time on or after the Effective Date and on or before the expiration or earlier termination of this Warrant, proposes to register under
the Act any shares of Common Stock held by one or more stockholders of the Company for resale by such stockholders, whether on a Form S-3 registration statement or otherwise, the Company shall give written notice thereof to Warrantholder and permit
Warrantholder to include any or all of the shares of Common Stock issuable upon exercise of this Warrant (and any or all shares previously issued to Warrantholder upon any prior exercise(s) hereof) in such registration on a pari passu basis
with such other stockholder(s) and on the same terms and conditions applicable to such other stockholder(s). 
 (h)
Information Rights. At all times (if any) during the term of this Warrant when (i) the Company shall not be required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, and/or
(ii) the Common Stock shall no longer be listed or quoted for trading on a national securities exchange or over-the-counter market, Warrantholder shall be entitled to the information rights contained in Section 7.1 of the Loan Agreement,
and in any such event Section 7.1 of the Loan Agreement is hereby incorporated into this Agreement by this reference as though fully set forth herein, provided, however, that the Company shall not be required to deliver a Compliance Certificate
once all Indebtedness (as defined in the Loan Agreement) owed by the Company to Warrantholder has been repaid. 
 SECTION
10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. 
 This Agreement has been entered into by the Company in reliance
upon the following representations and covenants of the Warrantholder: 
 (a) Investment Purpose. This Warrant and the
shares issued on exercise hereof will be acquired for investment and not with a view to the sale or distribution of any part thereof in violation of applicable federal and state securities laws, and the Warrantholder has no present intention of
selling or engaging in any public distribution of the same except pursuant to a registration or exemption. 
 (b) Private
Issue. The Warrantholder understands (i) that the Common Stock issuable upon exercise of this Agreement is not, as of the Effective Date, registered under the Act or qualified under applicable state securities laws, and (ii) that the
Company’s reliance on exemption from such registration is predicated on the representations set forth in this Section 10. 
 (c) Financial Risk. The Warrantholder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability
to bear the economic risks of its investment. 
 (d) Accredited Investor. Warrantholder is an “accredited
investor” within the meaning of the Securities and Exchange Rule 501 of Regulation D, as presently in effect. 
 (e) No
Short Sales. Warrantholder has not at any time on or prior to the Effective Date engaged in any short sales or equivalent transactions in the Common Stock. Warrantholder 

  
 6 

 
agrees that at all times from and after the Effective Date and on or before the expiration or earlier termination of this Warrant, it shall not engage in any short sales or equivalent
transactions in the Common Stock. 
 SECTION 11. TRANSFERS. 

Subject to compliance with applicable federal and state securities laws, this Agreement and all rights hereunder are transferable, in
whole or in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Agreement properly endorsed. Each taker and holder of this Agreement, by taking or holding the same, consents and agrees that this Agreement,
when endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Company’s books, shall be treated by the Company and all other persons dealing with
this Agreement as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Agreement. The transfer of this Agreement shall be recorded on the books of the Company upon receipt by the Company of
a notice of transfer in the form attached hereto as Exhibit III (the “Transfer Notice”), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Until
the Company receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes. 

SECTION 12. MISCELLANEOUS. 
 (a) Effective Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been executed and delivered by the Company on the date hereof. This
Agreement shall be binding upon any successors or assigns of the Company. 
 (b) Remedies. In the event of any default
hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific
performance for any default where Warrantholder will not have an adequate remedy at law and where damages will not be readily ascertainable. 
 (c) No Impairment of Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this
Agreement, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate in order to protect the rights of the Warrantholder against impairment. 

(d) [Intentionally Omitted] 
 (e) Attorney’s Fees. In any litigation, arbitration or court proceeding between the Company and the Warrantholder relating hereto, the prevailing party shall be entitled to attorneys’
fees and expenses and all costs of proceedings incurred in enforcing this Agreement. For the purposes of this Section 12(e), attorneys’ fees shall include without limitation fees incurred in connection with the following: (i) contempt
proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions
and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment. 
 (f)
Severability. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or
unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision. 

  
 7 

 (g) Notices. Except as otherwise provided herein, any notice, demand, request,
consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly
served, given, delivered, and received upon the earlier of: (a) personal delivery to the party to be notified, (b) when sent by confirmed telex, electronic transmission or facsimile if sent during normal business hours of the recipient, if
not, then on the next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized overnight courier, specifying
next day delivery, with written verification of receipt, and shall be addressed to the party to be notified as follows: 
 If to
Warrantholder: 
 HERCULES TECHNOLOGY GROWTH CAPITAL, INC. 

Legal Department 
 Attention: Chief Legal Officer and Manuel Henriquez 
 400 Hamilton Avenue, Suite
310 
 Palo Alto, CA 94301 
 Facsimile: 650-473-9194 
 Telephone: 650-289-3060 

If to the Company: 
 Coronado Biosciences, Inc. 
 Attention: Chief Financial Officer 

15 New England Executive Park 
 Burlington, MA 01803 
 Facsimile: 

Telephone: 781-238-6621 
 or to such other address as each party may designate for itself by like notice. 

(h) Entire Agreement; Amendments. This Agreement constitutes the entire agreement and understanding of the parties hereto in
respect of the subject matter hereof, and supersedes and replaces in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof. None of
the terms of this Agreement may be amended except by an instrument executed by each of the parties hereto. 
 (i)
Headings. The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of this Agreement or any provisions hereof. 

(j) Advice of Counsel. Each of the parties represents to each other party hereto that it has discussed (or had an opportunity to
discuss) with its counsel this Agreement and, specifically, the provisions of Sections 12(n), 12(o), 12(p). 12(q) and 12(r). 

(k) No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the
authorship of any provisions of this Agreement. 

  
 8 

 (l) No Waiver. No omission or delay by Warrantholder at any time to enforce any right
or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right or remedy to which Warrantholder is entitled, nor shall it in any way
affect the right of Warrantholder to enforce such provisions thereafter. 
 (m) Survival. All agreements, representations
and warranties contained in this Agreement or in any document delivered pursuant hereto shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination of this
Agreement. 
 (n) Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the
laws of the State of Delaware, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 
 (o) Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any state or federal court of competent jurisdiction located in
the Commonwealth of Massachusetts. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in Suffolk or Middlesex County, Commonwealth of Massachusetts;
(b) waives any objection as to jurisdiction or venue in Suffolk or Middlesex County, Commonwealth of Massachusetts; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and
(d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance
with the requirements for notice set forth in Section 12(g), and shall be deemed effective and received as set forth in Section 12(g). Nothing herein shall affect the right to serve process in any other manner permitted by law or shall
limit the right of either party to bring proceedings in the courts of any other jurisdiction. 
 (p) Mutual Waiver of Jury
Trial. Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than
arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM,
CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such
Claims, including Claims that involve persons or entities other the Company and Warrantholder; Claims that arise out of or are in any way connected to the relationship between the Company and Warrantholder; and any Claims for damages, breach of
contract, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement. 
 (q)
Arbitration. If the Mutual Waiver of Jury Trial set forth in Section 12(p) is ineffective or unenforceable, the parties agree that all Claims shall be submitted to binding arbitration in accordance with the commercial arbitration rules
of JAMS (the “Rules”), such arbitration to occur before one arbitrator, which arbitrator shall be a retired Delaware state judge or a retired Federal court judge. Such proceeding shall be conducted in Suffolk or Middlesex County,
Commonwealth of Massachusetts, with Massachusetts rules of evidence and discovery applicable to such arbitration. The decision of the arbitrator shall be binding on the parties, and 

  
 9 

 
shall be final and nonappealable to the maximum extent permitted by law. Any judgment rendered by the arbitrator may be entered in a court of competent jurisdiction and enforced by the prevailing
party as a final judgment of such court. 
 (r) Pre-arbitration Relief. In the event Claims are to be resolved by
arbitration, either party may seek from a court of competent jurisdiction identified in Section 12(o), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by
law notwithstanding that all Claims are otherwise subject to resolution by binding arbitration. 
 (s) Counterparts. This
Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of
which counterparts shall constitute but one and the same instrument. 
 (t) Specific Performance. The parties hereto
hereby declare that it is impossible to measure in money the damages which will accrue to Warrantholder by reason of the Company’s failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement shall
be specifically enforceable by Warrrantholder. If Warrantholder institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense
therein that Warrantholder has an adequate remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that such remedy at law exists. 
 (u) Lost, Stolen, Mutilated or Destroyed Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose
(which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original
contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone. 
 [Remainder of Page Intentionally Left Blank] 

  
 10 

 IN WITNESS WHEREOF, the parties hereto have caused this Warrant Agreement to be executed by
its officers thereunto duly authorized as of the Effective Date. 
  

							
		 	COMPANY:	 	CORONADO BIOSCIENCES, INC.
				
		 		 	By:	 	 /s/ Bobby W. Sandage, Jr.

		 		 	Name:	 	 Bobby W. Sandage, Jr., Ph.D

		 		 	Title:	 	 President and CFO

			
		 	WARRANTHOLDER:	 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
				
		 		 	By:	 	 /s/ K. Nicholas Martitsch

		 		 	Name:	 	 K. Nicholas Martitsch

		 		 	Title:	 	 Associate General Counsel

  
 11 

 EXHIBIT I 
 NOTICE OF EXERCISE 
  

	To:	[                            
            ] 

  

	(1)	The undersigned Warrantholder hereby elects to purchase
[                    ] shares of the Common Stock of
[                            ], pursuant to the terms of the Agreement dated the [    ]
day of [            ,         ] (the “Agreement”) between
[                            ] and the Warrantholder, and tenders herewith payment of the Purchase Price in
full, together with all applicable transfer taxes, if any. 

  

	(2)	Please issue a certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such other name as is specified below.

  

			
	  

	
	(Name)
	
	  

	(Address)

  

					
		
	WARRANTHOLDER:	 	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
			
		 	By:	 	  

		 	Name:	 	  

		 	Title:	 	  

  
 12 

 EXHIBIT II 
  

	1.	ACKNOWLEDGMENT OF EXERCISE 

 The
undersigned
[                                         
                   ], hereby acknowledge receipt of the “Notice of Exercise” from Hercules Technology Growth Capital, Inc., to purchase
[            ] shares of the Common Stock of
[                            ], pursuant to the terms of the Agreement, and further acknowledges that
[            ] shares remain subject to purchase under the terms of the Agreement. 
  

							
		 	COMPANY:	 	[                           
             ]
				
		 		 	By:	 	  

				
		 		 	Title:	 	  

				
		 		 	Date:	 	  

  
 13 

 EXHIBIT III 
 TRANSFER NOTICE 
 (To transfer or assign the foregoing Agreement execute this form and supply
required information. Do not use this form to purchase shares.) 
 FOR VALUE RECEIVED, the foregoing Agreement and all rights evidenced thereby
are hereby transferred and assigned to 
  

					
	  
	 	
	(Please Print)	 	
			
	whose address is	 	  
	 	
		
	 
  
	 	

  

							
		 	Dated:	 	  
	 	

							
				
		 	Holder’s Signature:	 	  
	 	
				
		 	Holder’s Address:	 	  
	 	
			
		 	  
	 	

  

					
	Signature Guaranteed:	 	  
	 	

 NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of
the Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Agreement.

  
 14Loan and Security Agreement

 Exhibit 10.39 
 LOAN AND SECURITY AGREEMENT 
 This LOAN AND SECURITY AGREEMENT is made and dated
as of August 28, 2012 and is entered into by and between CORONADO BIOSCIENCES, INC., a Delaware corporation (hereinafter referred to as the “Borrower”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation
(“Lender”). 
 RECITALS 
 A. Borrower has requested Lender to make available to Borrower a term loan in the aggregate principal amount of FIFTEEN MILLION DOLLARS ($15,000,000) (the “Term Loan”); and 

B. Lender is willing to make the Term Loan on the terms and conditions set forth in this Agreement. 

AGREEMENT 

NOW, THEREFORE, Borrower and Lender agree as follows: 
 SECTION 1. DEFINITIONS AND RULES OF CONSTRUCTION 

1.1 Unless otherwise defined herein, the following capitalized terms shall have the following meanings: 

“Account Control Agreement(s)” means any agreement entered into by and among the Lender, Borrower and a third party bank or
other institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account (other than (i) deposit accounts used exclusively for payroll provided that the amount on deposit therein shall at no time exceed the amount
necessary to fund the payroll for the next succeeding payroll cycle and (ii) “zero balance” accounts) or an account holding Investment Property and which grants Lender a perfected first priority security interest in the subject
account or accounts. 
 “ACH Authorization” means the ACH Debit Authorization Agreement in substantially the form of
Exhibit H. 
 “ACH Failure” means (ii) the failure of the Automated Clearing House (ACH) system to effect a
transfer of funds requested by Lender to be used to satisfy all or part of Borrower’s obligations to pay principal and interest due hereunder or (ii) a failure by Lender to initiate debit entries for the periodic payments of such principal
or interest. 
 “Advance(s)” means a Term Loan Advance. 

“Advance Date” means the Closing Date. 
 “Advance Request” means a request for an Advance submitted by Borrower to Lender in substantially the form of Exhibit A. 

  
 1 

 “Agreement” means this Loan and Security Agreement, as amended from time to time.

 “Amortization Date” means October 1, 2013; provided, however, that upon receipt by the Borrower of Positive
Phase II Results, the Amortization Date may be extended to April 1, 2014 at the option of the Borrower. 

“Assignee” has the meaning given to it in Section 11.13. 

“Borrower Products” means all products, software, service offerings, technical data or technology currently being designed,
manufactured or sold by Borrower or which Borrower intends to sell, license, or distribute in the future including any products or service offerings under development, collectively, together with all products, software, service offerings, technical
data or technology that have been sold, licensed or distributed by Borrower since its incorporation. 
 “Cash” means
all cash and liquid funds. 
 “Change in Control” means (i) reorganization, recapitalization, consolidation or
merger (or similar transaction or series of related transactions) of Borrower, (ii) any sale, exchange or other transfer by the stockholders of Borrower, in a single transaction or series of related transactions, whether pursuant to tender
offer, negotiated private sale or otherwise, of outstanding shares representing 50% or more of the then-outstanding total combined voting power of Borrower, (iii) the sale or issuance by Borrower of equity securities to one or more purchasers,
in a single transaction or series of related transactions not registered under the Securities Act of 1933, which securities represent, as of immediately following the closing (or, if there be more than one, any closing) thereof, 50% or more of the
then-outstanding total combined voting power of Borrower, or (iv) the sale, assignment, transfer or other disposition of all or substantially all of the assets of Borrower. 

“Claims” has the meaning given to it in Section 11.10. 

“Closing Date” means the date of this Agreement. 
 “Collateral” means the property described in Section 3. 

“Commitment Charge” means FORTY THOUSAND DOLLARS ($40,000.00), which fee has been paid by the Borrower to Lender prior to the
Closing Date. 
 “Confidential Information” has the meaning given to it in Section 11.12. 

“Contingent Obligation” means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that
Person with respect to (i) any indebtedness, lease, dividend, letter of credit or other obligation of another, including any such obligation directly or indirectly guaranteed, endorsed, co-made or discounted or sold with recourse by that
Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit, corporate credit cards or merchant services issued for the account of that Person; and
(iii) all obligations arising under any interest rate, currency or 

  
 2 

 
commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates,
currency exchange rates or commodity prices; provided, however, that the term “Contingent Obligation” shall not include endorsements for collection or deposit in the ordinary course of business. The amount of any Contingent Obligation
shall be deemed to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect
thereof as determined by such Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the obligations under the guarantee or other support arrangement. 

“Copyright License” means any written agreement granting any right to use any Copyright or Copyright registration, now owned
or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest. 
 “Copyrights”
means all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof, or of any other country. 
 “Deposit Accounts” means any “deposit accounts,” as such term is defined in the UCC, and includes any checking account, savings account, or certificate of deposit. 

“Equity Documents” means the Warrant and the Equity Rights Letter, as the same may from time to time be amended, modified,
supplemented or restated. 
 “Equity Rights Letter” means that certain letter agreement dated as of the date hereof
by and between Lender and Borrower in the form attached hereto as Exhibit I. 
 “ERISA” is the Employee Retirement
Income Security Act of 1974, and its regulations. 
 “Event of Default” has the meaning given to it in
Section 9. 
 “Excluded Collateral” has the meaning given to it in Section 3.1. 

“Facility Charge” means $150,000 (i.e., one percent (1.00%) of the Maximum Term Loan Amount). 

“Financial Statements” has the meaning given to it in Section 7.1. 

“GAAP” means generally accepted accounting principles in the United States of America, as in effect from time to time.

 “Indebtedness” means indebtedness of any kind, including (a) all indebtedness for borrowed money or the
deferred purchase price of property or services (excluding trade credit entered into in the ordinary course of business due within sixty (60) days), including reimbursement and other obligations with respect to surety bonds and letters of
credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations, and (d) all Contingent Obligations. 

  
 3 

 “Insolvency Proceeding” is any proceeding by or against any Person under the
United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief.

 “Intellectual Property” means all of Borrower’s Copyrights; Trademarks; Patents; Licenses; trade secrets and
inventions; mask works; Borrower’s applications therefor and reissues, extensions, or renewals thereof; and Borrower’s goodwill associated with any of the foregoing, together with Borrower’s rights to sue for past, present and future
infringement of Intellectual Property and the goodwill associated therewith. 
 “Investment” means any beneficial
ownership (including stock, partnership or limited liability company interests) of or in any Person, or any loan, advance or capital contribution to any Person or the acquisition of all, or substantially all, of the assets of another Person.

 “Joinder Agreements” means for each Subsidiary, a completed and executed Joinder Agreement in substantially the
form attached hereto as Exhibit G. 
 “Lender” has the meaning given to it in the preamble to this Agreement.

 “Lender Expenses” are all reasonable audit fees and expenses, costs, and expenses (including reasonable,
documented attorneys’ fees and expenses) for preparing, negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings). 

“License” means any Copyright License, Patent License, Trademark License or other license of rights or interests. 

“Lien” means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance,
levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, and any lease in the nature of a security interest.

 “Loan” means the Term Loan Advance made under this Agreement. 

“Loan Documents” means this Agreement, the Note, the ACH Authorization, the Account Control Agreements, the Joinder
Agreements, all UCC Financing Statements, any Subordination Agreement and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby (other than the Equity Documents), as the same may from time to
time be amended, modified, supplemented or restated. 
 “Material Adverse Effect” means a material adverse effect
upon: (i) the business, operations, properties, assets, prospects or condition (financial or otherwise) of Borrower; or (ii) the ability of Borrower to perform the Secured Obligations in accordance with the terms of the Loan Documents, or
the ability of Lender to enforce any of its rights or remedies with respect to the Secured Obligations; or (iii) the Collateral or Lender’s Liens on the Collateral or the priority of such Liens. Notwithstanding the foregoing, a
“Material Adverse Effect” shall not include any 

  
 4 

 
of the following, each in and of itself: (i) adverse test or trial result (whether related to safety or efficacy); (ii) interruption or delay in receiving clinical trial supplies or in
commencing or completing any clinical trials (including as a result of any action or proceeding by any regulatory agency) or any increased cost associated with a clinical trial; (iii) increase in Borrower’s operating losses or cash burn,
or decrease in Borrower’s cash balance, that is materially consistent with Borrower’s historical results or projected operating losses and/or cash burn; or (iv) an adverse change attributable to developments or conditions affecting
the pharmaceutical industry generally. 
 “Maximum Term Loan Amount” means FIFTEEN MILLION DOLLARS ($15,000,000).

 “Maximum Rate” shall have the meaning assigned to such term in Section 2.2. 

“Note(s)” means the Term Note. 
 “Patent License” means any written agreement granting any right with respect to any invention on which a Patent is in existence or a Patent application is pending, in which agreement Borrower
now holds or hereafter acquires any interest. 
 “Patents” means all letters patent of, or rights corresponding
thereto, in the United States or in any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United States or any other country. 

“Permitted Indebtedness” means: (i) Indebtedness of Borrower in favor of Lender arising under this Agreement, any other
Loan Document or any Equity Document; (ii) Indebtedness existing on the Closing Date which is disclosed in Schedule 1A; (iii) Indebtedness of up to $1,000,000 outstanding at any time secured by a lien described in clause (vii) of the
defined term “Permitted Liens,” provided such Indebtedness does not exceed the lesser of the cost or fair market value of the Equipment financed with such Indebtedness; (iv) Indebtedness to trade creditors incurred in the ordinary
course of business, including Indebtedness incurred in the ordinary course of business with corporate credit cards; (v) Indebtedness that also constitutes a Permitted Investment; (vi) Subordinated Indebtedness; (vii) reimbursement
obligations in connection with letters of credit that are secured by cash or cash equivalents and issued on behalf of the Borrower or a Subsidiary thereof in an amount not to exceed $250,000 at any time outstanding, (viii) other Indebtedness in
an amount not to exceed $500,000 at any time outstanding, and (ix) extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified to impose materially more
burdensome terms upon Borrower or its Subsidiary, as the case may be. 
 “Permitted Investment” means:
(i) Investments existing on the Closing Date which are disclosed in Schedule 1B; (ii) (a) marketable direct obligations issued or unconditionally guaranteed by the United States of America or any agency or any State thereof maturing
within one year from the date of acquisition thereof, (b) commercial paper maturing no more than one year from the date of creation thereof and currently having a rating of at least A-2 or P-2 from either Standard & Poor’s
Corporation or Moody’s Investors Service, (c) certificates of deposit issued by any bank with assets of at least $500,000,000 maturing no more than one year from the 

  
 5 

 
date of investment therein, and (d) money market and savings accounts; (iii) repurchases of stock from former employees, directors, or consultants of Borrower under the terms of
applicable repurchase agreements at the original issuance price of such securities in an aggregate amount not to exceed $100,000 in any fiscal year, provided that no Event of Default has occurred, is continuing or would exist after giving effect to
the repurchases; (iv) Investments accepted in connection with Permitted Transfers; (v) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of
delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower’s business; (vi) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to
customers and suppliers who are not affiliates, in the ordinary course of business, provided that this subparagraph (vi) shall not apply to Investments of Borrower in any Subsidiary; (vii) Investments consisting of loans not involving the
net transfer on a substantially contemporaneous basis of cash proceeds to employees, officers or directors relating to the purchase of capital stock of Borrower pursuant to employee stock purchase plans or other similar agreements approved by
Borrower’s Board of Directors; (viii) Investments consisting of travel advances to employees for business related expenses and other employee loans and advances in the ordinary course of business provided that the aggregate amount of
advances and loans pursuant to this clause (viii) shall not exceed $50,000 in any fiscal year; (ix) Investments in newly-formed Subsidiaries organized in the United States, provided that each such Subsidiary enters into a Joinder Agreement
promptly after their formation by Borrower and provides collateral security consistent with the collateral provided by Borrower hereunder and executes such other documents as shall be reasonably requested by Lender; (x) Investments in
subsidiaries organized outside of the United States approved in advance in writing by Lender; (xi) joint ventures, strategic alliances or licenses in the ordinary course of Borrower’s business consisting of the licensing of technology, the
development of technology or the providing of technical support (provided that such transactions do not result in a legal transfer of title by Borrower of any Intellectual Property), provided that any cash Investments by Borrower in respect of such
joint ventures or strategic alliances do not exceed $500,000 in the aggregate in any fiscal year; and (xii) additional Investments that do not exceed $500,000 in the aggregate throughout the term of this Agreement. 

“Permitted Liens” means any and all of the following: (i) Liens in favor of Lender; (ii) Liens existing on the
Closing Date which are disclosed in Schedule 1C; (iii) Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in good faith by appropriate proceedings; provided, that Borrower
maintains adequate reserves therefor in accordance with GAAP; (iv) Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other like Persons arising in the ordinary course of Borrower’s
business and imposed without action of such parties; provided, that the payment thereof is not yet required; (v) Liens arising from judgments, decrees or attachments in circumstances which do not constitute an Event of Default hereunder;
(vi) the following deposits, to the extent made in the ordinary course of business: deposits under worker’s compensation, unemployment insurance, social security and other similar laws, or to secure the performance of bids, tenders or
contracts (other than for the repayment of borrowed money) or to secure indemnity, performance or other similar bonds for the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure statutory
obligations (other than liens arising under ERISA or environmental liens) or surety or appeal bonds, or to secure indemnity, performance or other similar bonds; (vii) Liens on Equipment or software or

  
 6 

 
other intellectual property constituting purchase money liens and liens in connection with capital leases securing Indebtedness permitted in clause (iii) of “Permitted
Indebtedness”; (viii) Liens incurred in connection with Subordinated Indebtedness; (ix) leasehold interests in leases or subleases and licenses granted in the ordinary course of business and not interfering in any material respect
with the business of the licensor; (x) Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties that are promptly paid on or before the date they become due; (xi) Liens on insurance
proceeds securing the payment of financed insurance premiums that are promptly paid on or before the date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property or assets); (xii) statutory
and common law rights of set-off and other similar rights as to deposits of cash and securities in favor of banks, other depository institutions and brokerage firms; (xiii) easements, zoning restrictions, rights-of-way and similar encumbrances
on real property imposed by law or arising in the ordinary course of business so long as they do not materially impair the value or marketability of the related property; (xiv) Liens on cash or cash equivalents securing obligations permitted
under clause (vii) of the definition of Permitted Indebtedness; and (xv) Liens incurred in connection with the extension, renewal or refinancing of the indebtedness secured by Liens of the type described in clauses (i) through
(xi) above; provided, that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness being extended, renewed or refinanced (as may have been reduced
by any payment thereon) does not increase. 
 “Permitted Transfers” means (i) sales of Inventory in the normal
course of business, (ii) exclusive and non-exclusive licenses for the use of Intellectual Property in the ordinary course of business provided any such licenses do not or could not result in a legal transfer of title by Borrower of any
Intellectual Property owned by Borrower or the licensed property, (iii) dispositions of worn-out, obsolete or surplus Equipment at fair market value in the ordinary course of business, and (iv) other Transfers of assets having a fair
market value of not more than $250,000 in the aggregate in any fiscal year. 
 “Person” means any individual, sole
proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability company, institution, other entity or government. 
 “Positive Phase II Results” means, based on analysis of top-line results from the Borrower’s Phase II study of CNDO 201 in patients with active Crohn’s disease, the primary end-point
of such study was achieved and acceptable performance was demonstrated with the secondary end points. 
 “Prepayment
Charge” shall have the meaning assigned to such term in Section 2.4. 
 “Prime Rate” means the “prime
rate” as reported in the Wall Street Journal, and if not reported, then the prime rate most recently reported in the Wall Street Journal. 
 “Receivables” means (i) all of Borrower’s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, letters of credit, proceeds of any letter of credit, and Letter of
Credit Rights, and (ii) all customer lists, software, and business records related thereto. 

  
 7 

 “Secured Obligations” means Borrower’s obligations under this Agreement and
any Loan Document, including any obligation to pay any amount now owing or later arising. 
 “Subordinated
Indebtedness” means Indebtedness subordinated to the Secured Obligations in amounts and on terms and conditions satisfactory to Lender in its sole discretion. 
 “Subordination Agreement” means any subordination agreement entered into in connection with Subordinated Indebtedness in form and substance acceptable to Lender. 

“Subsequent Financing” has the meaning given to such term in the Equity Rights Letter. 

“Subsidiary” means an entity, whether corporate, partnership, limited liability company, joint venture or otherwise, in which
Borrower owns or controls more than 50% of the outstanding voting securities, including each entity listed on Schedule 1 hereto. 
 “Term Loan Advance” means any Term Loan funds advanced under this Agreement. 
 “Term Loan Interest Rate” means for any day with respect to the Term Loan a floating rate per annum equal to the greater of (i) 9.25% or (ii) the sum of (A) 9.25% and
(B) (1) the Prime Rate minus (2) 3.25%. The Term Loan Interest Rate will float and change on the day the Prime Rate changes from time to time. 
 “Term Loan Maturity Date” means March 1, 2016. 
 “Term
Note” means a Promissory Note in substantially the form of Exhibit B. 
 “Trademark License” means any written
agreement granting any right to use any Trademark or Trademark registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest. 

“Trademarks” means all trademarks (registered, common law or otherwise) and any applications in connection therewith,
including registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof. 

“UCC” means the Uniform Commercial Code as the same is, from time to time, in effect in the State of California; provided,
that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Lender’s Lien on any Collateral is governed by the Uniform Commercial Code as the same is,
from time to time, in effect in a jurisdiction other than the State of California, then the term “UCC” shall mean the Uniform Commercial Code as in effect, from time to time, in such other jurisdiction solely for purposes of the provisions
thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions. 
 “UK Subsidiary” means Innmune Limited, a private limited company and a wholly-owned subsidiary of Borrower. 

  
 8 

 “Warrant” means the warrant entered into in connection with the Loan. 

Unless otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a “Section,”
“subsection,” “Exhibit,” “Annex,” or “Schedule” shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement. Unless otherwise specifically provided herein, any
accounting term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in accordance with GAAP, consistently applied.
Unless otherwise defined herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC. 

SECTION 2. THE LOAN 
 2.1 Term Loan. 
 (a) Advance. Subject to the terms and conditions
of this Agreement, Lender will make, and Borrower agrees to draw, a Term Loan Advance of $15,000,000 on the Closing Date. The aggregate outstanding Term Loan Advance may not exceed the Maximum Term Loan Amount. 

(b) Advance Request. To obtain the Term Loan Advance, Borrower shall complete, sign and deliver an Advance Request (at
least five (5) business days before the Advance Date) and Term Note to Lender. Lender shall fund the Term Loan Advance in the manner requested by the Advance Request provided that each of the conditions precedent to such Term Loan Advance is
satisfied as of the requested Advance Date. 
 (c) Interest. The principal balance of the Term Loan Advance shall
bear interest thereon from such Advance Date at the Term Loan Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed. The Term Loan Interest Rate will float and change on the day
the Prime Rate changes from time to time. 
 (d) Payment. Borrower will pay interest on the Term Loan Advance on
the first day of each month, beginning the month after the Advance Date. Borrower shall repay the aggregate Term Loan principal balance that is outstanding on the Amortization Date in equal monthly installments of principal and interest (based on an
amortization period of thirty (30) months) beginning on the Amortization Date and continuing on the first business day of each month thereafter. The entire Term Loan principal balance and all accrued but unpaid interest hereunder, shall be due
and payable on Term Loan Maturity Date. Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to the Borrower’s account as
authorized on the ACH Authorization on each payment date of all periodic obligations payable to Lender under each Term Note or Term Advance. Once repaid, the Term Loan Advance or any portion thereof may not be reborrowed. 

  
 9 

 2.2 Maximum Interest. Notwithstanding any provision in this Agreement, the
Note, or any other Loan Document, it is the parties’ intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court of competent jurisdiction shall deem applicable hereto
(which under the laws of the State of California shall be deemed to be the laws relating to permissible rates of interest on commercial loans) (the “Maximum Rate”). If a court of competent jurisdiction shall finally determine that Borrower
has actually paid to Lender an amount of interest in excess of the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess interest actually paid by Borrower shall
be applied as follows: first, to the payment of principal outstanding on the Note; second, after all principal is repaid, to the payment of Lender’s accrued interest, costs, Lender Expenses, professional fees and any other Secured Obligations;
and third, after all Secured Obligations are repaid, the excess (if any) shall be refunded to Borrower. 
 2.3
Default Interest. In the event any payment is not paid on the scheduled payment date other than due to an ACH Failure, an amount equal to three percent (3.00%) of the past due amount shall be payable on demand. In addition, upon the occurrence
and during the continuation of an Event of Default hereunder, all Secured Obligations, including principal, interest, compounded interest, and professional fees, shall bear interest at a rate per annum equal to the rate set forth in
Section 2.1(c) plus five percent (5.00%) per annum. In the event any interest is not paid when due hereunder other than due to an ACH Failure, delinquent interest shall be added to principal and shall bear interest on interest, compounded
at the rate set forth in Section 2.1(c). 
 2.4 Prepayment. At its option upon at least 7 business days
prior notice to Lender, Borrower may prepay all or any portion of the outstanding Advance by paying the principal balance being prepaid, all accrued and unpaid interest thereon, all fees and Lender Expenses accrued to the date of the prepayment,
together with a prepayment charge equal to the following percentage of the principal amount of the Advance being prepaid: if the principal amount of the Advance being prepaid is prepaid in any of the first twelve (12) months following the
Closing Date, 3%; if prepaid after twelve (12) months but prior to twenty four (24) months, 2%; and if prepaid thereafter, but prior to the Term Loan Maturity Date, 1% (each, a “Prepayment Charge”). Borrower agrees that the
Prepayment Charge is a reasonable calculation of Lender’s lost profits in view of the difficulties and impracticality of determining actual damages resulting from an early repayment of the Advance. Borrower shall prepay the entire principal
balance, all accrued and unpaid interest thereon, all fees and Lender Expenses accrued to the date of the prepayment and the Prepayment Charge upon the occurrence of a Change in Control. 

2.5 End of Term Charge. On the earliest to occur of (i) the Term Loan Maturity Date, (ii) the date that Borrower
prepays the outstanding Secured Obligations in full, or (iii) the date that the Secured Obligations are accelerated and become due and payable, Borrower shall pay Lender a charge of Three Hundred Ninety Seven Thousand Five Hundred Dollars
($397,500) (i.e. two and sixty-five hundredths percent (2.65%) of the Maximum Term Loan Amount). Notwithstanding the required payment date of such charge, it shall be deemed earned by Lender as of the Closing Date. 

  
 10 

 SECTION 3. SECURITY INTEREST 

3.1 As security for the prompt, complete and indefeasible payment when due (whether on the payment dates or otherwise) of
all the Secured Obligations, Borrower grants to Lender a security interest in all of Borrower’s right, title, and interest in and to the following personal property whether now owned or hereafter acquired, including the following (collectively,
the “Collateral”): (a) Receivables; (b) Equipment; (c) Fixtures; (d) General Intangibles (other than Intellectual Property constituting Excluded Collateral); (e) Inventory; (f) Investment Property (but
excluding Investment Property consisting of the capital stock of the UK Subsidiary and thirty-five percent (35.00%) of the capital stock of any foreign Subsidiary that constitutes a Permitted Investment); (g) Deposit Accounts;
(h) Cash; (i) Goods; and all other tangible and intangible personal property of Borrower whether now or hereafter owned or existing, leased, consigned by or to, or acquired by, Borrower and wherever located, and any of Borrower’s
property in the possession or under the control of Lender; and, to the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the
foregoing; provided, however, the security interest grant hereunder shall not extend to and the term “Collateral” shall not include (such property so excluded from Collateral is referred to herein as the “Excluded
Collateral”): (1) the Intellectual Property; provided, further, that notwithstanding the foregoing, (x) the Collateral shall include all Accounts and General Intangibles that consist of rights to payment and proceeds from the
sale, licensing or disposition of all or any part, or rights in, the Intellectual Property (the “Rights to Payment”) and (y) if a court of competent jurisdiction (including a U.S. Bankruptcy Court) holds that it is necessary to have a
security interest in the Intellectual Property out of which such Rights to Payment arise in order to have a security interest in such Rights to Payment, then the Collateral shall automatically, and effective as of the date of this Agreement, include
that portion of the Intellectual Property to the extent necessary to permit perfection of Lender’s security interest in such Rights to Payment and (2) Investment Property consisting of Borrower’s equity interest in the UK Subsidiary.
In the event Lender obtains a security interest in any Intellectual Property under the immediately preceding clause “(y)”, then Lender shall not exercise any rights or remedies (under the UCC or otherwise) with respect to such Intellectual
Property except to the extent necessary to exercise rights and remedies in respect of Rights to Payment. 
 SECTION 4.
CONDITIONS PRECEDENT TO LOAN 
 The obligation of Lender to make the Term Loan Advance hereunder is subject to the
satisfaction by Borrower of the following conditions: 
 4.1 Term Loan Advance. On or prior to the Closing
Date, Borrower shall have delivered to Lender the following: 
 (a) originals of the Loan Documents executed by
the parties thereto, a legal opinion of Borrower’s counsel, and all other documents and instruments reasonably required by Lender to effectuate the transactions contemplated hereby or to create and perfect the Liens of Lender with respect to
all Collateral, in all cases in form and substance reasonably acceptable to Lender; 

  
 11 

 (b) certified copy of resolutions of Borrower’s board of directors
evidencing approval of (i) the Loan and other transactions evidenced by the Loan Documents; and (ii) the Equity Documents and transactions evidenced thereby; 

(c) certified copies of the Certificate of Incorporation and the Bylaws, as amended through the Closing Date, of Borrower;

 (d) a certificate of good standing for Borrower from its state of incorporation and similar certificates from
all other jurisdictions in which it does business and where the failure to be qualified would have a Material Adverse Effect; 
 (e) originals of the Equity Documents executed by the parties thereto; 
 (f) payment of the Facility Charge and reimbursement of all outstanding Lender Expenses reimbursable pursuant to this Agreement, which amounts, if not previously paid, may be deducted from the Advance;
and 
 (g) such other documents as Lender may reasonably request. 

4.2 All Advances. On the Advance Date: 

(a) Lender shall have received (i) an Advance Request and a Note for the relevant Advance as required by
Section 2.1(b), each duly executed by Borrower’s Chief Executive Officer or Chief Financial Officer, and (ii) any other documents Lender may reasonably request. 

(b) The representations and warranties set forth in this Agreement and in Section 5 and in the Warrant shall be true
and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date. 

(c) Borrower shall be in compliance with all the terms and provisions set forth herein and in each other Loan Document on
its part to be observed or performed, and at the time of and immediately after such Advance no Event of Default shall have occurred and be continuing. 
 (d) Each Advance Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date as to the matters specified in paragraphs (b) and (c) of this
Section 4.2 and as to the matters set forth in the Advance Request. 
 4.3 No Default. As of the Closing
Date and each Advance Date, (i) no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default and (ii) no event that has had or could reasonably be expected to
have a Material Adverse Effect has occurred and is continuing. 

  
 12 

 SECTION 5. REPRESENTATIONS AND WARRANTIES OF BORROWER 

Borrower represents and warrants that as of the Closing Date and, except to the extent otherwise provided below, the date of the delivery
by Borrower to Lender of each Compliance Certificate: 
 5.1 Corporate Status. Borrower is a corporation duly
organized, legally existing and in good standing under the laws of the State of Delaware, and is duly qualified as a foreign corporation in all jurisdictions in which the nature of its business or location of its properties require such
qualifications, except where the failure to be qualified could not reasonably be expected to have a Material Adverse Effect. Borrower’s present name, former names (if any), locations, state of incorporation, tax identification number,
organizational identification number and other information are correctly set forth in Exhibit C, as may be updated by Borrower in a written notice (including any Compliance Certificate) provided to Lender after the Closing Date. 

5.2 Collateral. Borrower owns the Collateral and owns or has exclusive license rights to the Intellectual Property, free
of all Liens, except for Permitted Liens. Borrower has the power and authority to grant to Lender a Lien in the Collateral as security for the Secured Obligations. 

5.3 Consents. Borrower’s execution, delivery and performance of the Note, this Agreement and all other Loan
Documents, and Borrower’s execution of the Equity Documents, (i) have been duly authorized by all necessary corporate action of Borrower, (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than
Permitted Liens and the Liens created by this Agreement and the other Loan Documents, (iii) do not violate any provisions of Borrower’s Certificate or Articles of Incorporation (as applicable), bylaws, or any, law, regulation, order,
injunction, judgment, decree or writ to which Borrower is subject and (iv) except as described on Schedule 5.3, do not violate any contract or agreement to which Borrower is a party or require the consent or approval of any other Person, other
than those consents or approvals which have been obtained. The individual or individuals executing the Loan Documents and the Equity Documents are duly authorized to do so. 

5.4 Material Adverse Effect. No event that has had or could reasonably be expected to have a Material Adverse Effect has
occurred and is continuing. Borrower is not aware of any event likely to occur that could reasonably be expected to result in a Material Adverse Effect. 
 5.5 Actions Before Governmental Authorities. There are no actions, suits or proceedings at law or in equity or by or before any governmental authority now pending or, to the knowledge of Borrower,
threatened against or affecting Borrower or its property, which if adversely determined would reasonably be expected to result in a Material Adverse Effect. 
 5.6 Laws. Borrower is not in violation of any law, rule or regulation, or in default with respect to any judgment, writ, injunction or decree of any governmental authority, where such violation or default
is reasonably expected to result in a Material Adverse Effect. Borrower is not in default in any manner under any provision of any agreement or instrument evidencing indebtedness in a principal amount in excess of $50,000, or any other material
agreement to which it is a party or by which it is bound. 

  
 13 

 5.7 Information Correct and Current. No information, report, Advance
Request, financial statement, exhibit or schedule furnished, by or on behalf of Borrower to Lender in connection with any Loan Document or included therein or delivered pursuant thereto contained, contains any material misstatement of fact or
omitted, omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were, are or will be made, not misleading at the time such statement was made or deemed made. Additionally, any
and all financial or business projections provided by Borrower to Lender shall be (i) provided in good faith and based on the most current data and information available to Borrower, and (ii) the most current of such projections approved
by Borrower’s Board of Directors. 
 5.8 Tax Matters. Except as described on Schedule 5.8, (a) Borrower
has filed all federal, state and local tax returns that it is required to file, (b) Borrower has duly paid or fully reserved for all taxes or installments thereof (including any interest or penalties) as and when due, which have or may become
due pursuant to such returns, and (c) Borrower has paid or fully reserved for any tax assessment received by Borrower for the three (3) years preceding the Closing Date, if any (including any taxes being contested in good faith and by
appropriate proceedings). 
 5.9 Intellectual Property Claims. Borrower is the sole owner of, or otherwise has
the right to use, the Intellectual Property. Except as described on Schedule 5.9,(i) each of the material Copyrights, Trademarks and Patents is valid and enforceable, (ii) no material part of the Intellectual Property has been judged invalid or
unenforceable, in whole or in part, and (iii) no claim has been made to Borrower that any material part of the Intellectual Property violates the rights of any third party. Exhibit D is a true, correct and complete list of each of
Borrower’s Patents, registered Trademarks, registered Copyrights, and material agreements under which Borrower licenses Intellectual Property from third parties (other than shrink-wrap software licenses), together with application or
registration numbers, as applicable, owned or licensed by Borrower or any Subsidiary, in each case as of the Closing Date. Borrower is not in material breach of, nor has Borrower failed to perform any material obligations under, any of the foregoing
contracts, licenses or agreements and, to Borrower’s knowledge, no third party to any such contract, license or agreement is in material breach thereof or has failed to perform any material obligations thereunder. 

5.10 Intellectual Property. Except as described on Schedule 5.10, Borrower has, or in the case of any proposed business,
will have, all material rights with respect to Intellectual Property necessary in the operation or conduct of Borrower’s business as currently conducted and proposed to be conducted by Borrower. Without limiting the generality of the foregoing,
and in the case of Licenses, except for restrictions that are unenforceable under Division 9 of the UCC, Borrower has the right, to the extent required to operate Borrower’s business, to freely transfer, license or assign Borrower’s owned
Intellectual Property without condition, restriction or payment of any kind (other than license payments in the ordinary course of business) to any third party, and Borrower owns 

  
 14 

 
or has the right to use, pursuant to valid licenses, all software development tools, library functions, compilers and all other third-party software and other items that are used in the design,
development, promotion, sale, license, manufacture, import, export, use or distribution of Borrower Products. 

5.11 Borrower Products. Except as described on Schedule 5.11, no Intellectual Property owned by Borrower or Borrower
Product has been or is subject to any actual or, to the knowledge of Borrower, threatened litigation, proceeding (including any proceeding in the United States Patent and Trademark Office or any corresponding foreign office or agency) or outstanding
decree, order, judgment, settlement agreement or stipulation that restricts in any manner Borrower’s use, transfer or licensing thereof or that may affect the validity, use or enforceability thereof. There is no decree, order, judgment,
agreement, stipulation, arbitral award or other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant any license or ownership interest in any future Intellectual Property related to the operation or
conduct of the business of Borrower or Borrower Products. Borrower has not received any written notice or claim, or, to the knowledge of Borrower, oral notice or claim, challenging or questioning Borrower’s ownership in any Intellectual
Property purported to be owned by Borrower (or to Borrower’s knowledge written notice of any claim challenging or questioning the ownership in any licensed Intellectual Property of the owner thereof) or suggesting that any third party has any
claim of legal or beneficial ownership with respect thereto nor, to Borrower’s knowledge, is there a reasonable basis for any such claim. Neither Borrower’s use of its Intellectual Property nor the production and sale of Borrower Products
infringes the Intellectual Property or other rights of others (unless Borrower has a valid license to use such Intellectual Property or other rights and Borrower’s use is permitted by the terms of such license and Borrower is otherwise in
compliance with such license). 
 5.12 Financial Accounts. Exhibit E, as may be updated by the Borrower in a
written notice provided to Lender after the Closing Date, is a true, correct and complete list of (a) all banks and other financial institutions at which Borrower maintains Deposit Accounts and (b) all institutions at which Borrower
maintains an account holding Investment Property, and such exhibit correctly identifies the name, address and telephone number of each bank or other institution, the name in which the account is held, a description of the purpose of the account, and
the complete account number therefor. 
 5.13 Employee Loans. Except to the extent otherwise permitted under
Section 7.8 (c), Borrower has no outstanding loans to any employee, officer or director of the Borrower nor has Borrower guaranteed the payment of any loan made to an employee, officer or director of the Borrower by a third party. 

5.14 Capitalization and Subsidiaries. Borrower’s capitalization as of the Closing Date is set forth on Schedule 5.14
annexed hereto. Borrower does not own any stock, partnership interest or other securities of any Person, except for Permitted Investments. Attached as Schedule 1, as may be updated by Borrower in a written notice provided after the Closing Date, is
a true, correct and complete list of each Subsidiary. 

  
 15 

 SECTION 6. INSURANCE; INDEMNIFICATION 

6.1 Coverage. Borrower shall cause to be carried and maintained commercial general liability insurance, on an occurrence
form, against risks customarily insured against in Borrower’s line of business. Such risks shall include the risks of bodily injury, including death, property damage, personal injury, advertising injury, and contractual liability per the terms
of the indemnification agreement found in Section 6.3. Borrower must maintain a minimum of $2,000,000 of commercial general liability insurance for each occurrence and $5,000,000 in the aggregate. Borrower has and agrees to maintain a minimum
of $2,000,000 of directors and officers’ insurance for each occurrence and $5,000,000 in the aggregate. So long as there are any Secured Obligations outstanding, Borrower shall also cause to be carried and maintained insurance upon the
Collateral, insuring against all risks of physical loss or damage howsoever caused, in an amount not less than the full replacement cost of the Collateral, provided that such insurance may be subject to standard exceptions and deductibles.

 6.2 Certificates. Borrower shall deliver to Lender certificates of insurance that evidence Borrower’s
compliance with its insurance obligations in Section 6.1 and the obligations contained in this Section 6.2. Borrower’s insurance certificate shall state Lender is an additional insured for commercial general liability, a loss payee
for all risk property damage insurance, subject to the insurer’s approval, and a loss payee for property insurance and additional insured for liability insurance that Borrower has acquired from such insurer. Attached to the certificates of
insurance will be additional insured endorsements for liability and lender’s loss payable endorsements for all risk property damage insurance and fidelity. Borrower shall endeavor to cause all certificates of insurance to provide for a minimum
of thirty (30) days advance written notice to Lender of cancellation or any other change adverse to Lender’s interests. Any failure of Lender to scrutinize such insurance certificates for compliance is not a waiver of any of Lender’s
rights, all of which are reserved. 
 6.3 Indemnity. Borrower agrees to indemnify and hold Lender and its
officers, directors, employees, agents, in-house attorneys, representatives and shareholders harmless from and against any and all claims, costs, expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities
based on liability in tort, including strict liability in tort), including reasonable attorneys’ fees and disbursements and other costs of investigation or defense (including those incurred upon any appeal), that may be instituted or asserted
against or incurred by Lender or any such Person as the result of credit having been extended, suspended or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection with or arising out of
the transactions contemplated hereunder and thereunder, or any actions or failures to act in connection therewith, or arising out of the disposition or utilization of the Collateral, excluding in all cases claims resulting solely from Lender’s
gross negligence or willful misconduct. Borrower agrees to pay, and to save Lender harmless from, any and all liabilities with respect to, or resulting from any delay in paying, any and all excise, sales or other similar taxes (excluding taxes
imposed on or measured by the net income of Lender) that may be payable or determined to be payable with respect to any of the Collateral or this Agreement. 

  
 16 

 SECTION 7. COVENANTS OF BORROWER 

Borrower agrees as follows: 
 7.1 Financial Reports. Borrower shall furnish to Lender the financial statements and reports listed hereinafter (the “Financial Statements”): 

(a) as soon as practicable (and in any event within 30 days) after the end of each month, unaudited interim and
year-to-date financial statements as of the end of such month (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows during the period from the filing of
Borrower’s most recent Form 10-Q or 10-K, as applicable, to the end of such month and notice of any occurrence that has had a Material Adverse Effect, all certified by Borrower’s Chief Executive Officer or Chief Financial Officer to the
effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject to normal year-end adjustments, and (iii) they do not contain certain non-cash items that are customarily
included in quarterly and annual financial statements; 
 (b) as soon as practicable (and in any event within 45
days) after the end of each calendar quarter (except the fourth calendar quarter of each fiscal year), unaudited interim and year-to-date financial statements as of the end of such calendar quarter (prepared on a consolidated and consolidating
basis, if applicable), including balance sheet and related statements of income and cash flows during the period from the filing of Borrower’s most recent Form 10-Q or 10-K, as applicable, to the end of such month and notice of any occurrence
that has had a Material Adverse Effect, certified by Borrower’s Chief Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, and
(ii) that they are subject to normal year-end adjustments; as well as the most recent capitalization table for Borrower, including the weighted average exercise price of employee stock options; 

(c) as soon as practicable (and in any event within one hundred fifty (150) days) after the end of each fiscal year,
audited financial statements as of the end of such year (prepared on a consolidated basis) (the “Year-End Financial Statements”), including balance sheet and related statements of income and cash flows, and setting forth in comparative
form the corresponding figures for the preceding fiscal year. The Year-End Financial Statements must be certified by a firm of independent certified public accountants (the “Auditor”) selected by Borrower and reasonably acceptable to
Lender and accompanied by a management report and unqualified opinion (other than a “going concern” qualification in respect of the fiscal years ending December 31, 2012 and December 31, 2013 due to a lack of liquidity) from such
Auditor. Lender acknowledges and agrees that the Borrower’s current Auditor, PricewaterhouseCoopers LLP, is acceptable for purposes of this Section 7.1(c); 

(d) as soon as practicable (and in any event within 30 days) after the end of each month, a Compliance Certificate in the
form of Exhibit F; 
 (e) promptly after the sending or filing thereof, as the case may be, copies of any
regular, periodic and special reports or registration statements that Borrower files 

  
 17 

 
with the Securities and Exchange Commission or any governmental authority that may be substituted therefor, or any national securities exchange. Documents required to be delivered pursuant to the
terms of this clause (e) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower provides Lender a link thereto; 

(f) at the same time and in the same manner as it gives to its directors, copies of all materials that Borrower provides
to its directors at or in advance of meetings of the Board of Directors (other than materials provided only to the executive committee of the Board of Directors or any information which Borrower’s Board of Directors determines in good faith and
upon advice of counsel could waive Borrower’s attorney-client privilege or which constitutes confidential information); and 
 (g) financial and business projections promptly following their approval by Borrower’s Board of Directors, as well as budgets, operating plans and other financial information reasonably requested by
Lender. 
 The executed Compliance Certificate may be sent via facsimile to Lender at (650) 473-9194 or via e-mail to bjadot
@herculestech.com. All Financial Statements required to be delivered pursuant to clauses (a), (b) and (c) shall be sent via e-mail to financialstatements@herculestech.com with a copy to bjadot@herculestech.com provided, that if e-mail
is not available or sending such Financial Statements via e-mail is not possible, they shall be sent via facsimile to Lender at: (866) 468-8916, attention Chief Credit Officer. 

7.2 Management Rights. Borrower shall permit any representative that Lender authorizes, including its attorneys and
accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of Borrower at reasonable times and upon reasonable notice during normal business hours at Borrower’s expense (provided that
Borrower shall not be responsible to reimburse Lender for more than two (2) such examinations in any calendar year unless and Event of Default has occurred and is continuing). In addition, any such representative shall have the right to meet
with management and officers of Borrower to discuss such books of account and records. In addition, Lender shall be entitled at reasonable times and intervals to consult with and advise the management and officers of Borrower concerning significant
business issues affecting Borrower. Such consultations shall not unreasonably interfere with Borrower’s business operations. The parties intend that the rights granted Lender shall constitute “management rights” within the meaning of
29 C.F.R Section 2510.3-101(d)(3)(ii), but that any advice, recommendations or participation by Lender with respect to any business issues shall not be deemed to give Lender, nor be deemed an exercise by Lender of, control over Borrower’s
management or policies. 
 7.3 Further Assurances. Borrower shall from time to time execute, deliver and file,
alone or with Lender, any financing statements, security agreements, collateral assignments, notices, control agreements, or other documents, in each case, to perfect or give the highest priority to Lender’s Lien on the Collateral. Borrower
shall from time to time procure any instruments or documents as may be requested by Lender, and take all further action that may be necessary or desirable, or that Lender may reasonably request, to

  
 18 

 
perfect and protect the Liens granted hereby and thereby. In addition, and for such purposes only, Borrower hereby authorizes Lender to execute and deliver on behalf of Borrower and to file such
financing statements, collateral assignments, notices, control agreements, security agreements and other documents without the signature of Borrower either in Lender’s name or in the name of Lender as agent and attorney-in-fact for Borrower.
Borrower shall protect and defend Borrower’s title to the Collateral and Lender’s Lien thereon against all Persons claiming any interest adverse to Borrower or Lender other than Permitted Liens. 

7.4 Compromise of Agreements. With respect to Accounts with a combined value in excess of twenty percent (20.00%) of
all of Borrower’s Accounts then outstanding, Borrower shall not (a) grant any material extension of the time of payment thereof, except in the ordinary course of business, (b) to any material extent, compromise, compound or settle the
same for less than the full amount thereof, except in the course of ordinary business, (c) release, wholly or partly, any Person liable for the payment thereof, except in the ordinary course of business, or (d) allow any credit or discount
whatsoever thereon other than trade discounts granted by Borrower in the ordinary course of business of Borrower. 
 7.5 Indebtedness. Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness, or
prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness, except for the conversion of Indebtedness into equity securities and the payment of cash in lieu of fractional shares in connection with
such conversion. 
 7.6 Collateral. Borrower shall at all times keep the Collateral, the Intellectual Property
and all other property and assets used in Borrower’s business or in which Borrower now or hereafter holds any interest free and clear from any legal process or Liens whatsoever (except for Permitted Liens), and shall give Lender prompt written
notice of any legal process affecting the Collateral, the Intellectual Property, such other property and assets, or any Liens thereon. Borrower shall cause its Subsidiaries to protect and defend such Subsidiary’s title to its assets from and
against all Persons claiming any interest adverse to such Subsidiary, and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary’s property and assets free and clear from any legal process or Liens whatsoever (except for
Permitted Liens), and shall give Lender prompt written notice of any legal process affecting such Subsidiary’s assets. Borrower shall not agree with any Person other than Lender not to encumber its property. 

7.7 Investments. Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person, or
permit any of its Subsidiaries so to do, other than Permitted Investments. 
 7.8 Distributions. Borrower shall
not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class of stock or other equity interest other than pursuant to employee, director or consultant repurchase plans or other similar agreements, in an aggregate amount not to
exceed $100,000 per year, or (b) declare or pay any cash dividend 

  
 19 

 
or make a cash distribution on any class of stock or other equity interest, except that a Subsidiary may pay dividends or make distributions to Borrower, or (c) lend money to, or guarantee
the payment of any loans made by third parties to, employees, officers or directors in excess of $100,000 in the aggregate or (d) waive, release or forgive any indebtedness owed by any employees, officers or directors in excess of $100,000 in
the aggregate. 
 7.9 Transfers. Except for Permitted Transfers, Borrower shall not voluntarily or
involuntarily transfer, sell, lease, license, lend or in any other manner convey any equitable, beneficial or legal interest in any material portion of its assets. 

7.10 Mergers or Acquisitions. Except in connection with a Permitted Investment, Borrower shall not merge or
consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into any other business organization (other than mergers or consolidations of a Subsidiary into another Subsidiary or into Borrower), or acquire, or permit any of its
Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person. 
 7.11
Taxes. Borrower and its Subsidiaries shall pay when due all taxes, fees or other charges of any nature whatsoever (together with any related interest or penalties) now or hereafter imposed or assessed against Borrower, Lender (other than taxes
imposed on or measured by the net income of Lender) or the Collateral or upon Borrower’s ownership, possession, use, operation or disposition thereof or upon Borrower’s rents, receipts or earnings arising therefrom. Borrower shall file on
or before the due date therefor all personal property tax returns in respect of the Collateral. Notwithstanding the foregoing, Borrower may contest, in good faith and by appropriate proceedings, taxes for which Borrower maintains adequate reserves
therefor in accordance with GAAP. 
 7.12 Corporate Changes. Neither Borrower nor any Subsidiary shall change its
corporate name, legal form or jurisdiction of formation without at least twenty (20) days’ prior written notice to Lender. Except as set forth on Exhibit C, neither Borrower nor any Subsidiary shall relocate its chief executive office or
its principal place of business unless: (i) it has provided prior written notice to Lender; and (ii) such relocation shall be within the continental United States. Borrower shall not relocate any item of Collateral (other than
(w) Permitted Transfers, (x) sales of Inventory in the ordinary course of business, (y) relocations of Equipment (except to the locations set forth on Exhibit C) having an aggregate value of up to $250,000 in any fiscal year, and
(z) relocations of Collateral from a location described on Exhibit C to another location described on Exhibit C) unless (i) it has provided prompt written notice to Lender, (ii) such relocation is within the continental United States
and, (iii) if such relocation is to a third party bailee, it has delivered a bailee agreement in form and substance reasonably acceptable to Lender.Deposit Accounts. Neither Borrower nor any Subsidiary shall maintain any Deposit Accounts, or
accounts holding Investment Property, except with respect to which Lender has an Account Control Agreement. 

7.13 Borrower shall notify Lender of each Subsidiary formed subsequent to the Closing Date and, within 15 days of
formation, shall cause any such Subsidiary organized under the laws of any State within the United States to execute and deliver to Lender a Joinder Agreement. 

  
 20 

 7.14 At no time shall Borrower make any Investment in the UK Subsidiary
other than cash reasonably necessary to finance the payment of any franchise fees, taxes, fees of professional advisors (including but not limited to attorneys and accountants) and other costs incurred in the ordinary course of business for the
purpose of maintaining the existence of the UK Subsidiary. At no time shall the UK Subsidiary incur any material indebtedness or own any material assets. 
 SECTION 8. RIGHT TO INVEST; RIGHT TO CONVERT 
 8.1
Lender shall have the right, in its discretion, to participate in a Subsequent Financing pursuant to the terms set forth in the Equity Rights Letter (the purchase price for such participation may, in the discretion of Borrower, be paid by means of
the conversion of a portion of the Loan pursuant to the terms set forth in the Equity Rights Letter). 
 SECTION 9. EVENTS
OF DEFAULT 
 The occurrence of any one or more of the following events shall be an Event of Default: 

9.1 Payments. Borrower fails to pay principal or interest or any other amount due under this Agreement, the Note or any of
the other Loan Documents when due and such default continues for three (3) Business after the due date thereof; or 
 9.2 Covenants. Borrower breaches or defaults in the performance of any covenant or Secured Obligation under this Agreement, the Note, or any of the other Loan Documents, and (a) with respect to a
default under any covenant under this Agreement (other than under Sections 6, 7.5, 7.6, 7.7, 7.8 or 7.9) such default continues for more than ten (10) days after the earlier of the date on which (i) Lender has given notice of such default
to Borrower and (ii) Borrower has actual knowledge of such default or (b) with respect to a default under any of Sections 6, 7.5, 7.6, 7.7, 7.8 or 7.9, the occurrence of such default; or 

9.3 Material Adverse Effect. The occurrence of any event or circumstance constituting a Material Adverse Effect; or

 9.4 Other Loan Documents. The occurrence of any default under any Loan Document or any other agreement between
Borrower and Lender and such default continues for more than ten (10) days after the earlier of (a) Lender has given notice of such default to Borrower, or (b) Borrower has actual knowledge of such default; or 

9.5 Representations. Any representation or warranty made by Borrower in any Loan Document or in the Warrant shall have
been false or misleading in any material respect when made; or 
 9.6 Insolvency. Borrower
(A) (i) shall make an assignment for the benefit of creditors; or (ii) shall be unable to pay its debts as they become due, or be unable to pay or 

  
 21 

 
perform under the Loan Documents, or shall become insolvent; or (iii) shall file a voluntary petition in bankruptcy; or (iv) shall file any petition, answer, or document seeking for
itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation pertinent to such circumstances; or (v) shall seek or consent to or acquiesce
in the appointment of any trustee, receiver, or liquidator of Borrower or of all or any substantial part (i.e., 33-1/3% or more) of the assets or property of Borrower; or (vi) shall cease operations of its business as its business has normally
been conducted, or terminate substantially all of its employees; or (vii) Borrower or its directors or majority shareholders shall take any action initiating any of the foregoing actions described in clauses (i) through (vi); or
(B) either (i) forty-five (45) days shall have expired after the commencement of an involuntary action against Borrower seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under
any present or future statute, law or regulation, without such action being dismissed or all orders or proceedings thereunder affecting the operations or the business of Borrower being stayed; or (ii) a stay of any such order or proceedings
shall thereafter be set aside and the action setting it aside shall not be timely appealed; or (iii) Borrower shall file any answer admitting or not contesting the material allegations of a petition filed against Borrower in any such
proceedings; or (iv) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such proceedings; or (v) forty-five (45) days shall have expired after the appointment, without the
consent or acquiescence of Borrower, of any trustee, receiver or liquidator of Borrower or of all or any substantial part of the properties of Borrower without such appointment being vacated; or 

9.7 Attachments; Judgments. Any portion of Borrower’s assets having a value of $100,000 is attached or seized, or a
levy is filed against any such assets, or a judgment or judgments is/are entered for the payment of money, individually or in the aggregate, of at least $250,000 and shall remain unsatisfied, unvacated or unstayed for a period of twenty
(20) days after the entry thereof, or Borrower is enjoined or in any way prevented by court order from conducting any part of its business; or 
 9.8 Other Obligations. The occurrence of any default under any agreement or obligation of Borrower involving any Indebtedness in the principal amount in excess of $50,000, or the occurrence of any default
under any agreement or obligation of Borrower that could reasonably be expected to have a Material Adverse Effect. 
 SECTION
10. REMEDIES 
 10.1 General. Upon and during the continuance of any one or more Events of Default,
(i) Lender may, at its option, accelerate and demand payment of all or any part of the Secured Obligations together with the Prepayment Charge and declare them to be immediately due and payable (provided, that upon the occurrence of an Event of
Default of the type described in Section 9.6, the Note and all of the Secured Obligations shall automatically be accelerated and made due and payable, in each case without any further notice or act), (ii) Lender may terminate any
commitment of Lender to make any further Advances hereunder, and (iii) Lender may notify any of Borrower’s account debtors to make payment directly to Lender, compromise the amount of any such account on

  
 22 

 
Borrower’s behalf and endorse Lender’s name without recourse on any such payment for deposit directly to Lender’s account. Lender may exercise all rights and remedies with respect
to the Collateral under the Loan Documents or otherwise available to it under the UCC and other applicable law, including the right to release, hold, sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the
Collateral and the right to occupy, utilize, process and commingle the Collateral. All Lender’s rights and remedies shall be cumulative and not exclusive. 
 10.2 Collection; Foreclosure. Upon the occurrence and during the continuance of any Event of Default, Lender may, at any time or from time to time, apply, collect, liquidate, sell in one or more sales,
lease or otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable preparation or processing, in such order as Lender may elect. Any such sale may be made either at public or private sale at
its place of business or elsewhere. Borrower agrees that any such public or private sale may occur upon ten (10) calendar days’ prior written notice to Borrower. Lender may require Borrower to assemble the Collateral and make it available
to Lender at a place designated by Lender that is reasonably convenient to Lender and Borrower. The proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall be applied by Lender in the following order of
priorities: 
 First, to Lender in an amount sufficient to pay in full Lender’s costs and professionals’ and
advisors’ fees and expenses as described in Section 11.11; 
 Second, to Lender in an amount equal to the then unpaid
amount of the Secured Obligations (including principal, interest, and the Default Rate interest), in such order and priority as Lender may choose in its sole discretion; and 
 Finally, after the full, final, and indefeasible payment in Cash of all of the Secured Obligations, to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives or as a
court of competent jurisdiction may direct. 
 Lender shall be deemed to have acted reasonably in the custody, preservation and disposition of
any of the Collateral if it complies with the obligations of a secured party under the UCC and applicable law. 

10.3 No Waiver. Lender shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or any
other Person, and Borrower expressly waives all rights, if any, to require Lender to marshal any Collateral. 

10.4 Cumulative Remedies. The rights, powers and remedies of Lender hereunder shall be in addition to all rights, powers
and remedies given by statute or rule of law and are cumulative. The exercise of any one or more of the rights, powers and remedies provided herein shall not be construed as a waiver of or election of remedies with respect to any other rights,
powers and remedies of Lender. 
 SECTION 11. MISCELLANEOUS 

11.1 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be
effective and valid under applicable law, but if any 

  
 23 

 
provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without
invalidating the remainder of such provision or the remaining provisions of this Agreement. 
 11.2 Notice.
Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication (including the delivery of Financial Statements) that is required, contemplated, or permitted under the Loan
Documents or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission by facsimile or hand delivery or
delivery by an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid, in each case addressed to the party to be notified as
follows: 
  

	 	(a)	If to Lender: 

 HERCULES
TECHNOLOGY GROWTH CAPITAL, INC. 
 Legal Department 
 Attention: Chief Legal Officer and Mr. Bryan Jadot 
 400 Hamilton Avenue,
Suite 310 
 Palo Alto, California 94301 
 Facsimile: 650-473-9194 
 Telephone: 650-289-3060 

 

	 	(b)	If to Borrower: 

 CORONADO
BIOSCIENCES, INC. 
 Attention:        Bobby W. Sandage, Jr., Ph.D., CEO and 

                Dale Ritter, Senior Vice President,
Finance 
 15 New England Executive Park 
 Burlington, Massachusetts 01803 
 Facsimile: 781-459-7788 

Telephone: 781-238-6621 / 781-238-6623 
 or to such other address as each party may designate for itself by like notice. 
 11.3 Entire Agreement; Amendments. This Agreement, the Note, and the other Loan Documents constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof
and thereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof or thereof (including Lender’s
proposal letter dated July 20, 2012). None of the terms of this Agreement, the Note or any of the other Loan Documents may be amended except by an instrument executed by each of the parties hereto. 

11.4 No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this
Agreement. In the event an ambiguity or question of intent 

  
 24 

 
or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by
virtue of the authorship of any provisions of this Agreement. 
 11.5 No Waiver. The powers conferred upon Lender
by this Agreement are solely to protect its rights hereunder and under the other Loan Documents and its interest in the Collateral and shall not impose any duty upon Lender to exercise any such powers. No omission or delay by Lender at any time to
enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver of any such right or remedy to which Lender is entitled, nor shall it in
any way affect the right of Lender to enforce such provisions thereafter. 
 11.6 Survival. All agreements,
representations and warranties contained in this Agreement, the Note and the other Loan Documents or in any document delivered pursuant hereto or thereto shall be for the benefit of Lender and shall survive the execution and delivery of this
Agreement and the expiration or other termination of this Agreement. 
 11.7 Successors and Assigns. The
provisions of this Agreement and the other Loan Documents shall inure to the benefit of and be binding on Borrower and its permitted assigns (if any). Borrower shall not assign its obligations under this Agreement, the Note or any of the other Loan
Documents without Lender’s express prior written consent, and any such attempted assignment shall be void and of no effect. Lender may assign, transfer, or endorse its rights hereunder and under the other Loan Documents without prior notice to
Borrower, and all of such rights shall inure to the benefit of Lender’s successors and assigns; provided, however, other than assignments to Lender’s U.S. affiliates and/or to U.S. financial institutions in connection with the sale and/or
liquidation of Lender’s loan portfolio, without Borrower’s prior written consent (which shall not be unreasonably withheld) Lender shall not be permitted to assign and/or transfer its rights hereunder or under any other Loan Document
unless an Event of Default has occurred and is continuing. 
 11.8 Governing Law. This Agreement, the Note and
the other Loan Documents have been negotiated and delivered to Lender in the State of California, and shall have been accepted by Lender in the State of California. Payment to Lender by Borrower of the Secured Obligations is due in the State of
California. This Agreement, the Note and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of
laws of any other jurisdiction. 
 11.9 Consent to Jurisdiction and Venue. All judicial proceedings (to the
extent that the reference requirement of Section 11.10 is not applicable) arising in or under or related to this Agreement, the Note or any of the other Loan Documents may be brought in any state or federal court located in the State of
California. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to nonexclusive personal jurisdiction in Santa Clara County, State of California; (b) waives any objection as to
jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any final judgment rendered
thereby in 

  
 25 

 
connection with this Agreement, the Note or the other Loan Documents. Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given
in accordance with the requirements for notice set forth in Section 11.2, and shall be deemed effective and received as set forth in Section 11.2. Nothing herein shall affect the right to serve process in any other manner permitted by law
or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction. 
 11.10
Mutual Waiver of Jury Trial / Judicial Reference. 
 (a) Because disputes arising in connection with complex
financial transactions are most quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved
by a judge applying such applicable laws. EACH OF BORROWER AND LENDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY,
“CLAIMS”) ASSERTED BY BORROWER AGAINST LENDER OR ITS ASSIGNEE OR BY LENDER OR ITS ASSIGNEE AGAINST BORROWER. This waiver extends to all such Claims, including Claims that involve Persons other than Borrower and Lender; Claims that arise
out of or are in any way connected to the relationship between Borrower and Lender; and any Claims for damages, breach of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other
Loan Document. 
 (b) If the waiver of jury trial set forth in Section 11.10(a) is ineffective or
unenforceable, the parties agree that all Claims shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a mutually acceptable referee or, if the parties cannot agree, a
referee selected by the Presiding Judge of the Santa Clara County, California. Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable to such proceeding. 

(c) In the event Claims are to be resolved by judicial reference, either party may seek from a court identified in
Section 11.9, any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial
reference. 
 11.11 Professional Fees. Borrower promises to pay Lender’s fees and expenses necessary to
finalize the loan documentation, including but not limited to reasonable attorneys fees, UCC searches, filing costs, and other miscellaneous expenses. In addition, Borrower promises to pay any and all reasonable attorneys’ and other
professionals’ fees and expenses (including fees and expenses of in-house counsel) incurred by Lender after the Closing Date in connection with or related to: (a) the Loan; (b) the administration, collection, or enforcement of the
Loan; (c) the amendment or modification of the Loan Documents; (d) any waiver, consent, release, or termination under the Loan Documents; 

  
 26 

 
(e) the protection, preservation, sale, lease, liquidation, or disposition of Collateral or the exercise of remedies with respect to the Collateral; (f) any legal, litigation,
administrative, arbitration, or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review thereof; and (g) any bankruptcy, restructuring, reorganization, assignment for the benefit of
creditors, workout, foreclosure, or other action related to Borrower, the Collateral, the Loan Documents, including representing Lender in any adversary proceeding or contested matter commenced or continued by or on behalf of Borrower’s estate,
and any appeal or review thereof. 
 11.12 Confidentiality. Lender acknowledges that certain items of Collateral
and the Intellectual Property and information provided to Lender by Borrower are confidential and proprietary information of Borrower, if and to the extent such information either (x) is marked as confidential by Borrower at the time of
disclosure, or (y) should reasonably be understood to be confidential (the “Confidential Information”). Accordingly, Lender agrees that any Confidential Information it may obtain in the course of acquiring, administering, or
perfecting Lender’s security interest in the Collateral shall not be used or disclosed to any other Person in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except that Lender may disclose any such
information: (a) to its own directors, officers, employees, accountants, counsel and other professional advisors and to its affiliates if Lender in its sole discretion determines that any such party should have access to such information in
connection with such party’s responsibilities in connection with the Loan or this Agreement and, provided that such recipient of such Confidential Information either (i) agrees to be bound by the confidentiality provisions of this
paragraph or (ii) is otherwise subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential Information; (b) if such information is generally available to the public; (c) if required or
appropriate in any report, statement or testimony submitted to any governmental authority having or claiming to have jurisdiction over Lender; (d) if required or appropriate in response to any summons or subpoena or in connection with any
litigation, to the extent permitted or deemed advisable by Lender’s counsel; (e) to comply with any legal requirement or law applicable to Lender; (f) to the extent reasonably necessary in connection with the exercise of any right or
remedy under any Loan Document, including Lender’s sale, lease, or other disposition of Collateral after default; (g) to any participant or assignee of Lender or any prospective participant or assignee; provided, that such participant or
assignee or prospective participant or assignee agrees in writing to be bound by this Section prior to disclosure; or (h) otherwise with the prior consent of Borrower; provided, that any disclosure made in violation of this Agreement shall not
affect the obligations of Borrower or any of its affiliates or any guarantor under this Agreement or the other Loan Documents. Lender acknowledges that from time to time during the term of this Agreement Lender may be in possession of material
non-public information relating to Borrower. 
 11.13 Assignment of Rights. Borrower acknowledges and understands
that Lender may sell and assign all or part of its interest hereunder and under the Note(s) and Loan Documents to any person or entity (an “Assignee”). After any such assignment the term “Lender” as used in the Loan Documents
shall mean and include such Assignee, and such Assignee shall be vested with all rights, powers and remedies of Lender hereunder with respect to the interest so assigned; but with respect to any such interest not so

  
 27 

 
transferred, Lender shall retain all rights, powers and remedies hereby given. No such assignment by Lender shall relieve Borrower of any of its obligations hereunder. Lender agrees that in the
event of any transfer by it of the Note(s), it will endorse thereon a notation as to the portion of the principal of the Note(s), which shall have been paid at the time of such transfer and as to the date to which interest shall have been last paid
thereon. As used in the first sentence of this Section 11.13, the term “Loan Documents” shall not include the Equity Rights Letter. 
 11.14 Revival of Secured Obligations. This Agreement and the Loan Documents shall remain in full force and effect and continue to be effective if any petition is filed by or against Borrower for
liquidation or reorganization, if Borrower becomes insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any significant part of Borrower’s assets, or if any payment or transfer of
Collateral is recovered from Lender. The Loan Documents and the Secured Obligations and Collateral security shall continue to be effective, or shall be revived or reinstated, as the case may be, if at any time payment and performance of the Secured
Obligations or any transfer of Collateral to Lender, or any part thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is recovered from, Lender or by any obligee of the Secured Obligations,
whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment, performance, or transfer of Collateral had not been made. In the event that any payment, or any part thereof, is rescinded,
reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations shall be deemed, without any further action or documentation, to have been revived and reinstated except to the extent of the full, final,
and indefeasible payment thereof to Lender in Cash. 
 11.15 Counterparts. This Agreement and any amendments,
waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall
constitute but one and the same instrument. 
 11.16 No Third Party Beneficiaries. No provisions of the Loan
Documents are intended, nor will be interpreted, to provide or create any third-party beneficiary rights or any other rights of any kind in any Person other than Lender and Borrower unless specifically provided otherwise herein, and, except as
otherwise so provided, all provisions of the Loan Documents will be personal and solely between the Lender and the Borrower. 
 11.17 Publicity. With Borrower’s prior written consent, which shall not be unreasonably withheld, Lender may use Borrower’s name and logo, and include a brief description of the relationship
between Borrower and Lender, in Lender’s marketing materials; provided, however, no consent will be required (either by Lender or Borrower) in connection with the filing of this Agreement (or any other Loan Document) with the Securities and
Exchange Commission or any similar or replacement governmental entity or other mandatory disclosures required by law. 

(SIGNATURES TO FOLLOW) 

  
 28 

 IN WITNESS WHEREOF, Borrower and Lender have duly executed and delivered this Loan and
Security Agreement as of the day and year first above written. 
  

			
	BORROWER:
	
	CORONADO BIOSCIENCES, INC., a Delaware corporation
		
	Signature:	 	 /s/ Bobby W. Sandage, Jr.

		
	Print Name:	 	 Bobby W. Sandage, Jr., Ph.D.

		
	Title:	 	 President and CEO

 Accepted in Palo Alto, California: 

 

			
	LENDER:
	
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
		
	Signature:	 	 /s/ K. Nicholas Martitsch

		
	Print Name:	 	 K. Nicholas Martitsch

		
	Title:	 	 Associate General Counsel

 Table of Exhibits and Schedules 
  

			
	Exhibit A:	  	Advance Request
		  	Attachment to Advance Request
		
	Exhibit B:	  	Term Note
		
	Exhibit C:	  	Name, Locations, and Other Information for Borrower
		
	Exhibit D:	  	Borrower’s Patents, Trademarks, Copyrights and Licenses
		
	Exhibit E:	  	Borrower’s Deposit Accounts and Investment Accounts
		
	Exhibit F:	  	Compliance Certificate
		
	Exhibit G:	  	Joinder Agreement
		
	Exhibit H:	  	ACH Debit Authorization Agreement
		
	Exhibit I:	  	Equity Rights Letter

  
 29 

			
	Schedule 1	  	Subsidiaries
	Schedule 1A	  	Existing Permitted Indebtedness
	Schedule 1B	  	Existing Permitted Investments
	Schedule 1C	  	Existing Permitted Liens
	Schedule 5.3	  	Consents, Etc.
	Schedule 5.5	  	Actions Before Governmental Authorities
	Schedule 5.8	  	Tax Matters
	Schedule 5.9	  	Intellectual Property Claims
	Schedule 5.10	  	Intellectual Property
	Schedule 5.11	  	Borrower Products
	Schedule 5.14	  	Capitalization

  
 30 

 EXHIBIT A 
 ADVANCE REQUEST 
  

									
	To:	  	Lender:	  		  	Date:        	  	August     , 2012
					
		  	Hercules Technology Growth Capital, Inc.	  		  		  	
		  	400 Hamilton Avenue, Suite 310	  		  		  	
		  	Palo Alto, CA 94301	  		  		  	
		  	Facsimile: 650-473-9194	  		  		  	
		  	Attn:	  		  		  	

 CORONADO BIOSCIENCES, INC., a Delaware corporation (“Borrower”) hereby requests from Hercules Technology Growth
Capital, Inc. (“Lender”) an Advance in the amount of FIFTEEN MILLION DOLLARS ($15,000,000 on August 28, 2012 (the “Advance Date”) pursuant to the Loan and Security Agreement between Borrower and Lender (the
“Agreement”). Capitalized words and other terms used but not otherwise defined herein are used with the same meanings as defined in the Agreement. 
 Please: 
  

									
	(a)	    	Issue a check payable to Borrower	  	  
	  	
					
		    	         or
	  		  		  	
				
	(b)	    	Wire Funds to Borrower’s account	  	  
	  	
				
		    	Bank:	  	  
	  	
		    	Address:	  	  
	  	
		    		  	  
	  	
		    	ABA Number:	  	  
	  	
		    	Account Number:	  	  
	  	
		    	Account Name:	  	  
	  	

 Borrower represents that the conditions precedent to the Advance set forth in the Agreement are satisfied
and shall be satisfied upon the making of such Advance, including but not limited to: (i) that no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing; (ii) that the
representations and warranties set forth in the Agreement and in the Warrant are and shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent
such representations and warranties expressly relate to an earlier date; (iii) that Borrower is in compliance with all the terms and provisions set forth in each Loan Document on its part to be observed or performed; and (iv) that as of
the Advance Date, no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default under the Loan Documents. Borrower understands and acknowledges that Lender has the right to
review the financial information supporting this representation and, based upon such review in its sole discretion, Lender may decline to fund the requested Advance. 

  
 31 

 Borrower hereby represents that Borrower’s corporate status and locations have not
changed since the date of the Agreement or, if the Attachment to this Advance Request is completed, are as set forth in the Attachment to this Advance Request. 
 Borrower agrees to notify Lender promptly before the funding of the Loan if any of the matters which have been represented above shall not be true and correct on the Advance Date and if Lender has
received no such notice before the Advance Date then the statements set forth above shall be deemed to have been made and shall be deemed to be true and correct as of the Advance Date. 

Executed as of August 28, 2012. 
  

			
	BORROWER: CORONADO BIOSCIENCES, INC., a Delaware corporation
		
	SIGNATURE:	 	  

 

			
	TITLE:	 	  

 

			
	PRINT NAME:	 	  

  
 32 

 ATTACHMENT TO ADVANCE REQUEST 

Dated: August     , 2012 
 Borrower hereby represents and warrants to Lender that Borrower’s current name and organizational status is as follows: 

 

			
	Name:	  	CORONADO BIOSCIENCES, INC., a Delaware corporation
		
	Type of organization:	  	Corporation
		
	State of organization:	  	Delaware

			
		
	Organizational Identification Number:	  	 4183018

 Borrower hereby represents and warrants to Lender that the street addresses, cities, states and postal codes of its
current locations are as follows: 

  
 33 

 EXHIBIT B 
 SECURED TERM PROMISSORY NOTE 
  

			
	$15,000,000	  	Advance Date: August 28, 2012
		
		  	Maturity Date: March 1, 2016

 FOR VALUE RECEIVED, CORONADO BIOSCIENCES, INC., a Delaware corporation, for itself and each of its
Subsidiaries (the “Borrower”) hereby promises to pay to the order of Hercules Technology Growth Capital, Inc., a Maryland corporation or the holder of this Note (the “Lender”) at 400 Hamilton Avenue, Suite 310, Palo Alto, CA
94301 or such other place of payment as the holder of this Secured Term Promissory Note (this “Promissory Note”) may specify from time to time in writing, in lawful money of the United States of America, the principal amount of FIFTEEN
MILLION DOLLARS ($15,000,000) or such other principal amount as Lender has advanced to Borrower, together with interest at a floating rate per annum equal to the greater of (i) 9.25% or (ii) the sum of (A) 9.25% and
(B) (1) the Prime Rate as reported in The Wall Street Journal minus (2) 3.25%, based upon a year consisting of 360 days, with interest computed daily based on the actual number of days in each month. 

This Promissory Note is the Note referred to in, and is executed and delivered in connection with, that certain Loan and Security
Agreement dated August 28, 2012, by and between Borrower and Lender (as the same may from time to time be amended, modified or supplemented in accordance with its terms, the “Loan Agreement”), and is entitled to the benefit and
security of the Loan Agreement and the other Loan Documents (as defined in the Loan Agreement), to which reference is made for a statement of all of the terms and conditions thereof. All payments shall be made in accordance with the Loan Agreement.
All terms defined in the Loan Agreement shall have the same definitions when used herein, unless otherwise defined herein. An Event of Default under the Loan Agreement shall constitute a default under this Promissory Note. 

Borrower waives presentment and demand for payment, notice of dishonor, protest and notice of protest under the UCC or any applicable
law. Borrower agrees to make all payments under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or defense. This Promissory Note has been negotiated and delivered to Lender and is payable in the State
of California. This Promissory Note shall be governed by and construed and enforced in accordance with, the laws of the State of California, excluding any conflicts of law rules or principles that would cause the application of the laws of any other
jurisdiction. 
 BORROWER: 
  

					
		 	CORONADO BIOSCIENCES, INC.	 	
		 	By:	 	
		 	Title:	 	

 EXHIBIT C 
 NAME, LOCATIONS, AND OTHER INFORMATION FOR BORROWER 
 1. Borrower
represents and warrants to Lender that Borrower’s current name and organizational status as of the Closing Date is as follows: 
  

					
	Name:	  	CORONADO BIOSCIENCES, INC.	  	
			
	Type of organization:	  	Corporation	  	
			
	State of organization:	  	Delaware	  	

					
			
	 Organizational Identification Number:
	  	 4183018
	  	

 2. Borrower represents and warrants to Lender that for five (5) years prior to the Closing Date,
Borrower did not do business under any other name or organization or form except the following: 
 Name: 

Used during dates of: 
 Type of Organization: 
 State of organization: 

Organizational Identification Number: 
 Borrower’s fiscal year ends on              
 Borrower’s federal employer tax identification number is:
                         
 3. Borrower represents and warrants to Lender that its chief executive office is located at
                        . 

 EXHIBIT F 
 COMPLIANCE CERTIFICATE 
 Hercules Technology Growth Capital, Inc. 

400 Hamilton Avenue, Suite 310 
 Palo Alto, CA
94301 
 Reference is made to that certain Loan and Security Agreement dated August 28, 2012 and all ancillary documents
entered into in connection with such Loan and Security Agreement all as may be amended from time to time, (hereinafter referred to collectively as the “Loan Agreement”) between Hercules Technology Growth Capital, Inc.
(“Hercules”) as Lender and CORONADO BIOSCIENCES, INC., a Delaware corporation (the “Company”) as Borrower. All capitalized terms not defined herein shall have the same meaning as defined in the Loan Agreement. 

The undersigned is an Officer of the Company, knowledgeable of all Company financial matters, and is authorized to provide certification
of information regarding the Company; hereby certifies that in accordance with the terms and conditions of the Loan Agreement, the Company is in compliance for the period ending
                     of all covenants, conditions and terms and hereby reaffirms that all representations and warranties contained therein are true
and correct in all material respects on and as of the date of this Compliance Certificate with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, after
giving effect in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations and warranties. Attached are the required documents supporting the above certification. The undersigned further certifies that
these are prepared in accordance with GAAP (except for the absence of footnotes with respect to unaudited financial statement and subject to normal year end adjustments) and are consistent from one period to the next except as explained below.

  

							
	REPORTING REQUIREMENT	  	REQUIRED	  	 CHECK IF

ATTACHED
	  	 
				
	Interim Financial Statements	  	Monthly within 30 days	  		  	
				
	Interim Financial Statements	  	Quarterly within 45 days	  		  	
				
	Audited Financial Statements	  	FYE within 150 days	  		  	

  

			
	Very Truly Yours,
	
	CORONADO BIOSCIENCES, INC.,
		
	By:	 	  

		
	Name:	 	  

		
	Its:	 	  

 EXHIBIT G 
 FORM OF JOINDER AGREEMENT 
 This Joinder Agreement (the “Joinder
Agreement”) is made and dated as of [            ], 20[    ], and is entered into by and between
                        ., a
                     corporation (“Subsidiary”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation, as a Lender.

 RECITALS 
 A. Subsidiary’s Affiliate, [                    ] (“Company”) [has entered/desires to
enter] into that certain Loan and Security Agreement dated August 28, 2012, with Lender, as such agreement may be amended (the “Loan Agreement”), together with the other agreements executed and delivered in connection therewith;

 B. Subsidiary acknowledges and agrees that it will benefit both directly and indirectly from Company’s execution of the
Loan Agreement and the other agreements executed and delivered in connection therewith; 
 AGREEMENT 

NOW THEREFORE, Subsidiary and Lender agree as follows: 
  

	1.	The recitals set forth above are incorporated into and made part of this Joinder Agreement. Capitalized terms not defined herein shall have the meaning provided in the
Loan Agreement. 

  

	2.	By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of the Loan Agreement the same as if it were the Borrower (as defined in the
Loan Agreement) under the Loan Agreement, mutatis mutandis, provided however, that Lender shall have no duties, responsibilities or obligations to Subsidiary arising under or related to the Loan Agreement or the other agreements executed and
delivered in connection therewith. Rather, to the extent that Lender has any duties, responsibilities or obligations arising under or related to the Loan Agreement or the other agreements executed and delivered in connection therewith, those duties,
responsibilities or obligations shall flow only to Company and not to Subsidiary or any other person or entity. By way of example (and not an exclusive list): (a) Lender’s providing notice to Company in accordance with the Loan Agreement
or as otherwise agreed between Company and Lender shall be deemed provided to Subsidiary; (b) a Lender’s providing an Advance to Company shall be deemed an Advance to Subsidiary; and (c) Subsidiary shall have no right to request an
Advance or make any other demand on Lender. 

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 [SIGNATURE PAGE TO JOINDER AGREEMENT] 

 

							
	SUBSIDIARY:	 		 	
			
	  
	 		 	
				
		 	By:	 		 	
		 	Name:	 		 	
		 	Title:	 		 	
				
		 	Address:	 		 	
				
		 	Telephone:	 	  
	 	
		 	Facsimile:	 	  
	 	

  

							
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
				
		 	By:	 	  
	 	
		 	Name:	 	  
	 	
		 	Title:	 	  
	 	

							
		
		 	Address:
		 	400 Hamilton Ave., Suite 310	 		 	
		 	Palo Alto, CA 94301	 		 	
		 	Facsimile: 650-473-9194	 		 	
		 	Telephone: 650-289-3060	 		 	

 EXHIBIT H 
 ACH DEBIT AUTHORIZATION AGREEMENT 
 Hercules Technology Growth Capital, Inc. 

400 Hamilton Avenue, Suite 310 
 Palo Alto, CA
94301 
 Re: Loan and Security Agreement dated August 28, 2012 between Coronado Biosciences, Inc. (“Borrower”)
and Hercules Technology Growth Capital, Inc. (“Company”) (the “Agreement”) 
 In connection with the above referenced
Agreement, the Borrower hereby authorizes the Company to initiate debit entries for the periodic payments due under the Agreement to the Borrower’s account indicated below. The Borrower authorizes the depository institution named below to debit
to such account. 
  

			
	 DEPOSITORY NAME
  

 
	  	BRANCH
	 CITY
  

 
	  	STATE AND ZIP CODE
	 TRANSIT/ABA NUMBER
  

 
	  	ACCOUNT NUMBER

 This authority will remain in full force and effect so long as any amounts are due under the Agreement. 

 

			
	  

	(Borrower)(Please Print)
		
	By:	 	  

		
	Date:	 	  

 This Agreement shall be governed by, and interpreted and enforced in accordance with, the
laws of the State of California, excluding its conflicts of law provisions that would cause the application of the laws of any other jurisdiction. 
  

			
	Very truly yours,
	
	 CORONADO BIOSCIENCES, INC.

		
	 By:
	 	  

 
			
		
	 Name:
	 	
		
	 Title:
	 	

 Acknowledged and agreed to: 

 

							
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
				
		 	By:	 	  
	 	
		 	Name:	 	  
	 	
		 	Title:	 	  
	 	

					
			
		 	Address:	 	
		 	 400 Hamilton Ave., Suite 310

Palo Alto, CA 94301
	 	
		 	Facsimile: 650-473-9194	 	
		 	Telephone: 650-289-3060

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}]]